FISCHER MEDICAL VENTURE L
Latest filings
- Chan Sing En appointed independent director at Singapore subsidiary · Management Changes
- Postal Ballot: NCD issue of Rs 350 cr, borrowing cap hike to Rs 1000 cr · Board & Shareholder Meetings
- Quarterly RTA Certificate Under SEBI Depositories Regulations Submitted · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
Markets and distributes advanced medical imaging and neurosurgical technologies through subsidiaries and associates. Its wholly-owned subsidiary Time Medical International Ventures (India) supplies MRI systems, intraoperative MRI suites (including the AI-enabled DRIS-iMRI Medharanya Suite for neurosurgery combining AR, AI, ML and Exoscope technologies), Exoscope systems, and brain aneurysm screening solutions. Through associate Nanomedic Technologies, it holds exclusive India and Southeast Asia distribution rights for the Spincare portable electrospun wound care system, which received CDSCO import approval as India's first such clearance for a portable electrospun wound care device. The company operates as a single reportable segment under Ind AS 108, and reported FY26 revenue of Rs. 308.58 crore with net profit of Rs. 31.02 crore. A partnership with the WFNS Innovation & Technology Committee, the first such formal industry tie-up in the committee's history, supports global training and knowledge-sharing in neurosurgical technologies. On the cost side, materials account for 20.2% of revenue and other operating expenses for 34.9%, with employee cost at 4.9% and depreciation at 1.0%. A Rs. 358.46 crore preferential issue has funded imaging technology growth and general corporate purposes, with Rs. 280.93 crore deployed by March 2026.
Scorecard
Measured from the filed financials, judged against its Medical Equipment & Supplies peers · as of FY26 — not investment advice
Strengths
Nothing stands out in the filed numbers.Concerns
Charts
How has the market priced it — with filings on the timeline?
FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from FISCHER MEDICAL VENTURE L's filed financials and exchange disclosures
What does FISCHER MEDICAL VENTURE L do?
FISCHER MEDICAL VENTURE L is a Healthcare Equipment & Supplies company listed on NSE and BSE, trading under the symbol FISCHER.
Is FISCHER MEDICAL VENTURE L profitable?
Yes. Over the trailing twelve months FISCHER MEDICAL VENTURE L reported a net profit of ₹30 Cr on revenue of ₹367 Cr.
Does FISCHER MEDICAL VENTURE L pay a dividend?
Yes. The dividend yield is 0.02% at the current price. It paid out 1% of its profit as dividend in FY26.
Is FISCHER MEDICAL VENTURE L debt-free?
No. It reported borrowings of ₹72 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹60 Cr after cash. Debt stands at 0.19× equity. That is higher than 70% of its 11 Medical Equipment & Supplies peers.
Is FISCHER MEDICAL VENTURE L expensive compared with its peers?
On trailing P/E, FISCHER MEDICAL VENTURE L ranks 4 of 16 in Medical Equipment & Supplies — cheaper than 80% of them, against an industry median of 21.3×. This is a position, not a valuation judgement.
How much does the FISCHER MEDICAL VENTURE L share price move in a day?
On a typical session FISCHER MEDICAL VENTURE L moves 2.05% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
Where can I track FISCHER MEDICAL VENTURE L's announcements?
Every NSE and BSE filing by FISCHER MEDICAL VENTURE L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.